Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
46.62
+0.40 (0.87%)
At close: Apr 28, 2026, 4:00 PM EDT
48.00
+1.38 (2.96%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Corcept Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corcept Therapeutics stock have an average target of 96.5, with a low estimate of 60 and a high estimate of 121. The average target predicts an increase of 106.99% from the current stock price of 46.62.
Analyst Consensus: Buy
* Price targets were last updated on Mar 26, 2026.
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $100 → $110 | Strong Buy | Maintains | $100 → $110 | +135.95% | Mar 26, 2026 |
| Wolfe Research | Wolfe Research | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Mar 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $67 → $60 | Strong Buy | Maintains | $67 → $60 | +28.70% | Mar 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $67 → $60 | Strong Buy | Maintains | $67 → $60 | +28.70% | Feb 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $105 → $67 | Strong Buy | Maintains | $105 → $67 | +43.72% | Feb 20, 2026 |
Financial Forecast
Revenue This Year
960.00M
from 761.41M
Increased by 26.08%
Revenue Next Year
1.22B
from 960.00M
Increased by 26.98%
EPS This Year
0.54
from 0.82
Decreased by -33.82%
EPS Next Year
1.45
from 0.54
Increased by 166.60%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.1B | 1.5B | ||||||
| Avg | 960.0M | 1.2B | ||||||
| Low | 886.9M | 949.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 38.4% | 58.3% | ||||||
| Avg | 26.1% | 27.0% | ||||||
| Low | 16.5% | -1.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.93 | 3.07 | ||||||
| Avg | 0.54 | 1.45 | ||||||
| Low | 0.20 | 0.35 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.0% | 465.0% | ||||||
| Avg | -33.8% | 166.6% | ||||||
| Low | -76.1% | -35.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.